Fingerprint
Dive into the research topics of 'A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
Eric P. Brass, Leslie T. Cooper, Roger E. Morgan, William R. Hiatt
Research output: Contribution to journal › Article › peer-review
11
Scopus
citations